Clinical Trials Logo

Bioavailability clinical trials

View clinical trials related to Bioavailability.

Filter by:

NCT ID: NCT04139928 Completed - Bioavailability Clinical Trials

Bioavailability of Single-dose Magnesium Salts

Start date: August 1, 2018
Phase: N/A
Study type: Interventional

Magnesium plays a role in an array of critical body functions, controls normal adenosine triphosphate function, the metabolism of glucose, and cardiac muscle function, as well as the maintenance of cell membrane function. Low magnesium intakes and blood levels have been associated with a number of chronic diseases including hypertension, type 2 diabetes, metabolic syndrome, vascular disease, osteoporosis, and colon cancer. Magnesium deficiency is common. In the U.S. population, nearly 4% of men and 7% of women have hypomagnesemia (typically defined as a serum concentration <0.75 mmol/L, or < 17mg/L), which has been previously shown to be associated with an increased risk of all-cause mortality after 30 years of follow-up. In addition, hypomagnesemia is seen in approximately 11% of hospitalized patients and 52% of patients in coronary care units. Approximately half of the U.S. population does not currently reach the estimated average requirement (EAR) for magnesium from food. Yet magnesium deficiency is often overlooked. Magnesium is relatively well absorbed by the gut; oral bioavailability varies from 35 to 70% and depends on a variety of factors such as the form of the magnesium salt (organic vs. inorganic), its rate and extent of uptake from the intestine into the blood, and its transfer into tissues because magnesium is primarily an intracellular cation. The absorption rate increases when dietary intake is low. In terms of the effectiveness of oral dietary supplements, bioavailability and tolerability of various formulations are important considerations. Similar bioavailability has been demonstrated between inorganic formulations (magnesium oxide vs. magnesium chloride), however some studies have shown magnesium oxide to be less bioavailable. Diarrhea and abdominal cramping are side effects that are commonly reported from oral oral supplementation. These symptoms are thought to be due to the osmotic activity of unabsorbed salts in the intestine and colon and the stimulation of gastric motility. A new picometer-ionic form of magnesium chloride, was developed to efficiently deliver stabilized magnesium ions that are similar in size to plant magnesium. Picometer magnesium is smaller in diameter than the body's cell mineral ion channels, therefore it has the potential to be completely absorbed and not cause adverse side effects in the gastrointestinal system (e.g., diarrhea). The aim of this research is to assess the bioavailability of this new picometer-ionic form of magnesium chloride by comparing its bioavailability to that of a standard magnesium oxide and magnesium citrate supplement in healthy, adult, normotensive subjects.

NCT ID: NCT04113564 Completed - Bioavailability Clinical Trials

Absolute Oral Bioavailability of Remimazolam

Start date: November 3, 2015
Phase: Phase 1
Study type: Interventional

A randomized, open-label, single-dose, 2-way crossover study to compare the relative bioavailability of orally administered remimazolam to an intravenous formulation in healthy volunteers

NCT ID: NCT04103788 Completed - Bioavailability Clinical Trials

Evaluation of Increased Absorption of a Curcumin Emulsion (CurQ+) in Healthy Volunteers

Start date: March 27, 2018
Phase: N/A
Study type: Interventional

This study is intended to evaluate the comparative effects of direct analysis of serum samples versus pre-treatment with enzymatic hydrolysis in split samples obtained from dosing with a highly absorbed curcumin emulsion product that is commercially available as BIOCURC.

NCT ID: NCT04097808 Completed - Bioavailability Clinical Trials

Impact of the Source and Food Matrices on the Bioavailability of Peptan® (Collagen Peptides) in Healthy Subjects

Start date: September 20, 2019
Phase: N/A
Study type: Interventional

The aim of this study is the comparison of the oral bioavailability of hydroxyproline, a key marker for collagen peptide intake, after ingestion of collagen peptides from different sources, sizes and together with different food matrices, either containing high or low levels of polyphenols.

NCT ID: NCT04028739 Completed - Bioavailability Clinical Trials

Theracurmin vs Curcumin Bioavailability Study

Start date: July 31, 2019
Phase: N/A
Study type: Interventional

A randomized, open-label, cross-over, single administration study to compare bioavailability of curcumin in health adults

NCT ID: NCT03915626 Completed - Bioavailability Clinical Trials

Effect of Heat on Rivastigmine TDS Products

Start date: October 4, 2019
Phase: Early Phase 1
Study type: Interventional

This research study is designed to measure the amount of medicine in blood over time after the patch is placed on the skin with and without external heat application.

NCT ID: NCT03485885 Completed - Bioavailability Clinical Trials

Bioavailability of Maqui Berry Extract (MBE) in Healthy Subjects

Start date: November 23, 2017
Phase:
Study type: Observational

The aim of the present study is to describe the bioavailability for the proprietary standardized maqui berry extracts Delphinol® and MaquiBright® enriched in anthocyanins and in particular delphinidins. The analyses are based on two selected key substances namely delphinidin-3-glucoside and cyanidin-3-sambubioside and their metabolism to phenolic acids. The bioavailability of anthocyanins specific for Delphinol®/MaquiBright® was analyzed in plasma sample kinetics (at 0h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h and 8h after intake of 1000mg standardized maqui berry extract in capsules) in 12 healthy subjects.

NCT ID: NCT03443076 Completed - Bioavailability Clinical Trials

Bioavailability of EPA + DHA in a SMEDS Formulation

Start date: February 16, 2018
Phase: N/A
Study type: Interventional

This study will assess the relative bioavailability of 500 mg eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) in a self-micro-emulsifying delivery system (SMEDS) formulation compared with a standard omega-3-acid ethyl ester product in healthy men and women.

NCT ID: NCT03323593 Completed - Dexmedetomidine Clinical Trials

Pharmacokinetics of Different Mode Administration of Intranasal Dexmedetomidine

Start date: May 2013
Phase: Phase 3
Study type: Interventional

Intranasal dexmedetomidine has been studied and used in children for premedication before anaesthesia or fro sedation. It can be administered by simple dripping or by Mucosal Atomization Device (MAD®). Since MAD® delivers intranasal medication in a fine mist, it is possible that absorption and bioavailability would be better compares to simple dripping method. To date no pharmacokinetic information of intranasal dexmedetomidine delivered by either method is available. This investigation is designed to compare the bioavailablity of intranasal dexmedetomidine deliver via simple dipping with tuberculine syringe and MAD® in healthy adults.

NCT ID: NCT03218631 Completed - Bioavailability Clinical Trials

Oxandrolone in Healthy Adults: A Relative Bioavailability Study

Start date: July 10, 2017
Phase: Phase 1
Study type: Interventional

To assess the pharmacokinetics and relative bioavailability of a single dose of approximately 0.1 mg/kg of a medium chain triglyceride (MCT) oil oxandrolone solution vs. tablets in a small cohort of healthy adults.